INNATE PHARMA SP.ADR/1 (F:IDDA) — Market Cap & Net Worth
Market Cap & Net Worth: INNATE PHARMA SP.ADR/1 (IDDA)
INNATE PHARMA SP.ADR/1 (F:IDDA) has a market capitalization of $116.15 Million (€99.35 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #18627 globally and #1723 in its home market, demonstrating a -26.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INNATE PHARMA SP.ADR/1's stock price €1.06 by its total outstanding shares 93724668 (93.72 Million).
INNATE PHARMA SP.ADR/1 Market Cap History: 2019 to 2026
INNATE PHARMA SP.ADR/1's market capitalization history from 2019 to 2026. Data shows change from $608.14 Million to $126.01 Million (-22.29% CAGR).
INNATE PHARMA SP.ADR/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INNATE PHARMA SP.ADR/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IDDA by Market Capitalization
Companies near INNATE PHARMA SP.ADR/1 in the global market cap rankings as of May 3, 2026.
Key companies related to INNATE PHARMA SP.ADR/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
INNATE PHARMA SP.ADR/1 Historical Marketcap From 2019 to 2026
Between 2019 and today, INNATE PHARMA SP.ADR/1's market cap moved from $608.14 Million to $ 126.01 Million, with a yearly change of -22.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €126.01 Million | -20.69% |
| 2025 | €158.88 Million | -22.46% |
| 2024 | €204.90 Million | -25.20% |
| 2023 | €273.93 Million | -22.36% |
| 2022 | €352.83 Million | -17.86% |
| 2021 | €429.53 Million | +24.05% |
| 2020 | €346.25 Million | -43.06% |
| 2019 | €608.14 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of INNATE PHARMA SP.ADR/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.15 Million USD |
| MoneyControl | $116.15 Million USD |
| MarketWatch | $116.15 Million USD |
| marketcap.company | $116.15 Million USD |
| Reuters | $116.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more